Skip to main content

Lupus clinical trials at UCSF

3 in progress, 1 open to eligible people

Lupus is a disease where your body's defense system attacks your own tissues. UCSF is studying a medicine called Obinutuzumab in teenagers with severe lupus kidney problems. UCSF is also checking the safety of this drug in children.

Showing trials for
  • Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

    open to eligible people ages 5-17

    This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.

    San Francisco, California and other locations

  • IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)

    Sorry, not currently recruiting here

    This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with active, refractory lupus nephritis and systemic lupus erythematosus. IMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Individual participants will remain in the active post-treatment period for approximately 1 year. Participants will continue in long-term follow-up for 15 years from treatment.

    San Francisco, California and other locations

  • VIBRANT: VIB4920 for Active Lupus Nephritis

    Sorry, in progress, not accepting new patients

    This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

    San Francisco, California and other locations

Our lead scientists for Lupus research studies include .

Last updated: